Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ChemGenex Of Australia Seeks Capital To Bolster Key Licensing Deal

This article was originally published in PharmAsia News

Executive Summary

Australia's ChemGenex plans to bolster its negotiating position with multinational pharmaceutical companies by raising enough capital to give it leverage in a licensing deal. At stake is ChemGenex's leukemia drug omacetaxine nearing completion of Phase III trials. CEO Greg Collier said the firm's intention is to get as much value for the drug as it can while pursuing licensing deals, negotiations for which he said are going well and would enable ChemGenex to retain some rights. The firm expects to submit its application for U.S. approval by mid-year. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts